3 hours Barclays Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $60.00 MarketBeat
Barclays increased their price target on Revolution Medicines from $54.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday.
Barclays increased their price target on Revolution Medicines from $54.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday.